Proprietary AI analyst is now available

Etropal Valuation Multiples

Discover revenue and EBITDA valuation multiples for Etropal and similar public comparables like Balsm Alofoq, Prolight Diagnostics, Farmaceutica Remedia, iZafe Group and more.

Etropal Overview

About Etropal

Etropal AD is engaged in the business of manufacturing medical accessories. The product portfolio includes fistula needles, blood taking sets, transfusion and infusion sets, catheters and tubes, urine collecting bags, colostomy bags, among others. The company also produces hip - joint endoprosthesis and instruments of implantation.


Founded

1976

HQ

Bulgaria

Employees

168

Website

etropal.eu

Financials (FY)

Revenue: $12M
EBITDA: $834K

EV

$14M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Etropal Financials

Etropal reported last fiscal year revenue of $12M and EBITDA of $834K.

In the same fiscal year, Etropal generated $4M in gross profit, $834K in EBITDA, and $183K in net income.


Etropal P&L

In the most recent fiscal year, Etropal reported revenue of $12M and EBITDA of $834K.

Etropal is profitable as of last fiscal year, with gross margin of 30%, EBITDA margin of 7%, and net margin of 1%.

See analyst estimates for Etropal
Last FY202320242025202620272028
Revenue$12M$7M$10M$12M
Gross Profit$4M$2M$3M$4M
Gross Margin30%36%30%30%
EBITDA$834K$673K$748K$834K
EBITDA Margin7%10%8%7%
EBIT Margin4%2%3%4%
Net Profit$183K($17K)$54K$183K
Net Margin1%(0%)1%1%
Net Debt$4M---

Financial data powered by Morningstar, Inc.

Etropal Stock Performance

Etropal has current market cap of $14M, and enterprise value of $14M.

Market Cap Evolution


Etropal's stock price is $2.89.

Etropal share price increased by 7.7% in the last 30 days, and decreased by 40.4% in the last year.

Etropal has an EPS (earnings per share) of $0.04.

See more trading valuation data for Etropal
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$14M$14M9.4%7.7%6.4%-40.4%$0.04

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Etropal Valuation Multiples

Etropal trades at 1.2x EV/Revenue multiple, and 17.3x EV/EBITDA.

See NTM and 2027E valuation multiples for Etropal

Etropal Financial Valuation Multiples

As of June 23, 2026, Etropal has market cap of $14M and EV of $14M.

Etropal has a P/E ratio of 79.0x.

Last FY202320242025202620272028
EV/Revenue1.2x2.1x1.5x1.2x
EV/EBITDA17.3x21.5x19.3x17.3x
EV/EBIT27.6x122.1x43.7x27.6x
EV/Gross Profit4.0x5.9x5.0x4.0x
P/E79.0xn/mn/m79.0x
EV/FCF(165.0x)26.2x46.2x(165.0x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Etropal Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Etropal Margins & Growth Rates

In the most recent fiscal year, Etropal reported gross margin of 30%, EBITDA margin of 7%, and net margin of 1%.

See estimated margins and future growth rates for Etropal

Etropal Margins

Last FY20242025202720282029
Gross Margin30%30%30%
EBITDA Margin7%8%7%
EBIT Margin4%3%4%
Net Margin1%1%1%
FCF Margin(1%)3%(1%)

Etropal Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth41%28%
Gross Profit Growth17%25%
EBITDA Growth11%11%
EBIT Growth180%58%
Net Profit Growth(418%)240%
FCF Growth(43%)(128%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Etropal Operational KPIs

Etropal's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.

Access forward-looking KPIs for Etropal
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$0.0M---
S&M Expenses to Revenue0%0%0%0%
G&A Expenses to Revenue2%2%1%2%
Opex to Revenue25%35%27%25%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Etropal Competitors

Etropal competitors include Balsm Alofoq, Prolight Diagnostics, Farmaceutica Remedia, iZafe Group, Ortivus, Cuprina Holdings (Cayman), Jin Medical International, BPC Instruments, BioRegenx and Airway Medix.

Most Etropal public comparables operate across Medical Supplies.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Balsm Alofoq2.4x-13.0x-
Prolight Diagnostics--(4.1x)-
Farmaceutica Remedia0.0x-1.4x-
iZafe Group26.9x-(14.3x)-
Ortivus2.5x-(12.4x)-
Cuprina Holdings (Cayman)219.4x-(2.4x)-
Jin Medical International0.4x-8.7x-
BPC Instruments1.8x-8.4x-

This data is available for Pro users. Sign up to see all Etropal competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Etropal

When was Etropal founded?Etropal was founded in 1976.
Where is Etropal headquartered?Etropal is headquartered in Bulgaria.
How many employees does Etropal have?As of today, Etropal has over 168 employees.
Is Etropal publicly listed?Yes, Etropal is a public company listed on Bulgarian Stock Exchange.
What is the stock symbol of Etropal?Etropal trades under ETR ticker.
When did Etropal go public?Etropal went public in 2007.
Who are competitors of Etropal?Etropal main competitors include Balsm Alofoq, Prolight Diagnostics, Farmaceutica Remedia, iZafe Group, Ortivus, Cuprina Holdings (Cayman), Jin Medical International, BPC Instruments, BioRegenx, Airway Medix.
What is the current market cap of Etropal?Etropal's current market cap is $14M.
What is the current revenue of Etropal?Etropal's last fiscal year revenue is $12M.
What is the current EV/Revenue multiple of Etropal?Current revenue multiple of Etropal is 1.2x.
Is Etropal profitable?No, Etropal is not profitable.
How many companies Etropal has acquired to date?Etropal hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Etropal has invested to date?Etropal hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Etropal

Lists including Etropal

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial